Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an ...

Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with Merck's (MRK) immuno-oncology agent Keytruda significantly improved ...

Now, Gilead argues that the “significant and meaningful” improvement in progression-free survival as shown in Ascent-04 “further reinforces the potential of Trodelvy plus Keytruda as a much ...

In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hoped.

Trodelvy + Keytruda improved progression-free survival over chemo + Keytruda in PD-L1+ metastatic TNBC. No new safety signals reported in ASCENT-04; overall survival trends will be tracked with ...

That shows how the company is now overvalued in our view. The largest risk to our thesis is if Gilead Sciences can achieve ...

However, in the ASCENT-04 study, there was an early trend in improvement for OS with Trodelvy plus Keytruda. Gilead will continue to monitor OS outcomes, with ongoing patient follow-up and further ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

You can reach Adam on Signal at stataf.54. Gilead Sciences said Monday that a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women with a less ...

Gilead Sciences recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, highlighting significant benefits in treating metastatic triple-negative breast cancer. This ...

Sales of cancer drug Trodelvy fell 5% to $293 million, below analysts' estimates of $362 million, due to pricing and inventory issues. Cell therapy product sales fell 3% to $464 million, which Gilead ...